BCMA-Binding Molecule Architecture for Lower Cytokine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BCMA-binding molecules, such as antibody-drug conjugates and bispecific BCMA-CD3 molecules, pose a risk of life-threatening cytokine release syndrome (CRS) and require BCMA-binding molecules with improved safety profiles while maintaining efficacy.
Innovation Solution
Development of monospecific and multispecific BCMA-binding molecules, including antibodies and antigen-binding fragments, that specifically target BCMA and other antigens like CD3, with improved safety features and extended in vivo half-life, connected by short peptide linkers or Fc domains, and used in drug conjugates and pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCMA-binding molecules (antibody-drug conjugates, bispecific BCMA-CD3 molecules) are used to target BCMA-expressing cells, then therapeutic efficacy against cancers is improved, but life-threatening cytokine release syndrome occurs
Solution Approach 1:
The patent introduces a Fc domain as an intermediary component in the BCMA-binding molecule structure. This Fc domain mediates controlled interaction with immune cells while reducing uncontrolled cytokine release. The Fc domain acts as a buffer that modulates the immune response, allowing therapeutic efficacy while mitigating the harmful cytokine release syndrome through controlled effector cell engagement.
2Measurement precision
If BCMA-binding molecules are used to treat cancers, then tumor cell targeting is improved, but safety profile deteriorates due to severe side effects
Solution Approach 1:
The patent applies local quality by creating heterogeneity in the BCMA-binding molecule structure through domain engineering. Different domains (BCMA-binding domain, Fc domain, linker regions) are optimized with distinct properties - the BCMA-binding domain provides high affinity for target cells, while the Fc domain provides controlled immune modulation. This local optimization of different molecular regions achieves both precise targeting and improved safety profile simultaneously.
3Adaptability or versatility
If monospecific and multispecific BCMA-binding molecules are developed, then therapeutic versatility is improved, but molecular complexity increases
Solution Approach 1:
The patent implements universality by designing a modular BCMA-binding molecule architecture where a standardized Fc domain and linker framework serve multiple functions across different molecule variants. The reusable Fc domain provides consistent immune modulation properties, while modular BCMA-binding domains can be swapped to create monospecific, bispecific, or multispecific molecules. This universal framework reduces overall molecular complexity despite increased therapeutic versatility.
Solution Approach 2:
The patent applies segmentation by dividing the BCMA-binding molecule into distinct functional domains: BCMA-binding domains, Fc domains, and linker regions. This segmentation allows independent optimization of each domain's function while maintaining overall molecular stability. The modular segmented structure enables systematic construction of complex multispecific molecules without proportionally increasing overall complexity, as each segment follows standardized design principles.
Data Source
AI summary
The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.